

# UC Irvine

## UC Irvine Previously Published Works

### Title

A brief review of intradialytic hypotension with a focus on survival.

### Permalink

<https://escholarship.org/uc/item/4r363113>

### Journal

Seminars in dialysis, 30(6)

### ISSN

0894-0959

### Authors

Chou, Jason A  
Kalantar-Zadeh, Kamyar  
Mathew, Anna T

### Publication Date

2017-11-01

### DOI

10.1111/sdi.12627

### Copyright Information

This work is made available under the terms of a Creative Commons Attribution License, available at <https://creativecommons.org/licenses/by/4.0/>

Peer reviewed



Published in final edited form as:

*Semin Dial.* 2017 November ; 30(6): 473–480. doi:10.1111/sdi.12627.

## A Brief Review of Intradialytic Hypotension with a Focus on Survival

Jason A. Chou<sup>1</sup>, Kamyar Kalantar-Zadeh<sup>1,2,3</sup>, and Anna T. Mathew<sup>4</sup>

<sup>1</sup>Harold Simmons Center for Kidney Disease Research and Epidemiology, Division of Nephrology and Hypertension

<sup>2</sup>Fielding School of Public Health at UCLA, Los Angeles, California

<sup>3</sup>Los Angeles Biomedical Research Institute at Harbor-UCLA, Torrance, California

<sup>4</sup>Division of Nephrology, Northwell Health, Great Neck, New York

### Abstract

Intradialytic hypotension (IDH), a common complication of ultrafiltration during hemodialysis therapy, is associated with high mortality and morbidity. IDH, defined as a nadir systolic blood pressure of less than 90 mmHg on more than 30% of treatments, is a relevant definition and is correlated with mortality. Risk factors for IDH include patient demographics, anti-hypertensive medication use, larger interdialytic weight gain, and dialysis prescription features as dialysate sodium, high ultrafiltration rate, and dialysate temperature. A high frequency of IDH events carries a substantial death risk. An ultrafiltration rate >10mL/hr/kg, and even more so >13mL/hr/kg, is highly predictive of cardiovascular and all-cause mortality. Evidence suggests that IDH causes acute reversible segmental myocardial hypoperfusion and contractile dysfunction (myocardial stunning), which can result in long-term loss of myocardial contractility, leading to premature death. IDH also has negative end-organ effects on the brain and gut, contributing to mortality through stroke, and endotoxin translocation with associated inflammation and protein-energy wasting. Given strong association of IDH and dialysis mortality, a paradigm shift to its approach is urgently needed. Randomized controlled trials are required to prospectively test drugs and monitoring devices which may reduce IDH.

### Keywords

Intradialytic hypotension; blood pressure; hemodialysis; mortality; ultrafiltration

### Background and Definition

Nephrologists have battled the well-known hemodialysis complication of intradialytic hypotension (IDH) in all settings and forms of hemodialysis. It is seen in acute inpatient and outpatient maintenance treatments and also in continuous and intermittent treatments. The

---

Correspondence: Anna T Mathew, MD, MPH, FRCP(C), Associate Professor of Medicine, Hofstra Northwell School of Medicine, Division of Nephrology, Northwell Health, 100 Community Drive, 2<sup>nd</sup> Floor, Great Neck, NY, amathew13@northwell.edu, Tel: (516) 465-8200, Fax: (516) 465-8202.

National Kidney Foundation Disease Outcomes and Quality Initiative (KDOQI) has defined IDH as a drop in systolic blood pressure (SBP) of greater than or equal to 20 mm Hg or mean arterial pressure of greater than or equal to 10 mm Hg, presence of end-organ ischemia, and requirement for intervention to increase blood pressure or improve symptoms.<sup>1</sup> Kooman et al. similarly defined IDH in their 2007 European Best Practices Guidelines (EBPG) for IDH.<sup>2</sup> In both these clinician-oriented guideline definitions, there was a requirement for a clinical event requiring an intervention.

More recently, observational studies on large population cohorts have been considering various BP-only definitions of IDH where the nadir and absolute change in intradialytic blood pressure have been used.<sup>3–5</sup> Flythe et al. has recently studied these discrepancies in defining IDH and the utility of nadir-SBP based definitions of IDH.<sup>3</sup> In their study, nadir-based IDH definitions, cut-off SBPs of 90 and 100 mmHg, did show the most consistent association with mortality in the HEMO and large dialysis organization (LDO) cohorts that were studied. The use of nadir-SBP based IDH definitions are gaining popularity in the literature as they allow for large population cohort studies which may or may not have access to nursing intervention information. As these studies shed more light on the associations of nadir-SBP and mortality, they may provide clinicians with greater guidance on nadir-SBP cut-offs for IDH.

The frequency of IDH in in-center hemodialysis traditionally has been cited to be about 20% in reviews<sup>6,7</sup> though individual studies have a varying frequency of 5–30%.<sup>8–11</sup> Recent studies by Sands et al. are similar to these reports. In their study of 1137 patients with 44,807 total treatments, the frequency of IDH was 17.2% in total where patient IDH frequency variability was high. There were 75% of patients with at least one episode of IDH and 58.8% patients had a IDH frequency of 1–35% and 16.2% of patients had >35% IDH frequency.<sup>12</sup> With the use of varying IDH definitions, the frequency of IDH can vary dramatically from 10–70%. Flythe et al.'s study of various IDH definitions in the HEMO cohort and a LDO cohort showed “nadir-only” definitions had an IDH frequency of about 10% where “SBP drop only” definitions of IDH had a greater frequency of 50–69%. In 2014, Silversides et al. did find in 472 ICU patients requiring renal replacement therapy, 87.3% of patients had at least one or more IDH events.<sup>13</sup>

## Pathophysiology of Intradialytic Hypotension

In its simplest form, IDH occurs when dialysis ultrafiltration exceeds the rate of plasma refill from normal physiologic compensatory mechanisms. Typically when there is decreased effective plasma volume with ultrafiltration, blood pressure is maintained by increasing plasma refill, vascular resistance, and cardiac output. IDH occurs when this corrective mechanism is insufficiently activated relative to ultrafiltration rate (UFR).

Plasma refill or venous capacity is largely controlled by decreased regional filling and venoconstriction that is actively and reflexively mediated. Normally, decreased regional filling can increase venous return by the DeJager-Krogh phenomenon.<sup>6,14</sup> Here, blood supply is shifted centrally by a passive recoil of regional venous beds which decreases their capacity; the splanchnic and cutaneous vascular beds assist the most in increasing venous

return. The shifted blood volume is then able to increase cardiac preload. In addition to increasing vascular resistance to the splanchnic and cutaneous vascular beds, in hypovolemia, there is also increased vascular resistance to the renal and skeletal vascular beds to assist with further venous return and thus increasing cardiac output.<sup>6</sup>

Cardiac output is also affected by the heart rate and contractility, but perhaps less so than dictated by conventional wisdom. Heart rate itself seems to have a modest effect in improving cardiac output in both animal and humans.<sup>15–17</sup> Contractility as well seems to have a minor role in cardiac output. In animal studies that removed the ability of the animal to respond to hypovolemia with increase cardiac inotropy via anesthesia or denervation of the beta-adrenergic response, the animals had little change in hemodynamic response to simulated hypovolemia.<sup>16–18</sup> In human patients, Ie et al. observed no difference in myocardial contractility in those with or without frequent episodes of IDH.<sup>19</sup> As such, the main driving force for cardiac output is preload or venous return where increasing heart rate and contractility may be of only limited benefit.<sup>6</sup>

Dysregulation of these physiologic compensatory mechanisms will then result in hypotension and IDH in dialysis patients. Patients with impaired cardiac function such as those with systolic and/or diastolic dysfunction are likely to have decreased cardiac output which further contributed to their risk for IDH. In studies of UFR in patients with and without systolic dysfunction, there were higher rates of BP drops in patients with systolic dysfunction.<sup>20,21</sup> Left ventricular hypertrophy and diastolic dysfunction were also found to be worse in patients more prone to IDH.<sup>21,22</sup>

Autonomic dysfunction and impaired baroreceptor sensitivity can limit the compensatory cardiac responses in IDH as well. In patients with reduce cardiac output and stroke volume, hemodialysis patients maintain the MAP by increasing total peripheral resistance; this may be due to background sympathetic over-activity<sup>23</sup>, a well recognized phenomenon in kidney disease patients.<sup>24</sup> Additionally, in patients with impaired baroreceptor response, as in those with increased sympathetic overactivity<sup>25</sup>, there is a tendency to have increase peripheral resistance versus patients without autonomic dysfunction.<sup>23,26–28</sup> Given that IDH prone patients have an increased total peripheral resistance during dialysis already, these patients may not be able to mount an increase in their peripheral resistance to compensate for further decreases in blood volume and maintain their MAP. This reduced baroreceptor variability found in CKD and ESRD patients is also associated with increased hemodynamic instability and sudden cardiac death.<sup>29</sup>

## Risk Factors of IDH

In healthy individuals, these hemodynamic mechanisms can be compensated for up to a 20% decline in circulating blood volume before hypotension occurs<sup>30,31</sup> but in dialysis patients much smaller declines of blood volume can be tolerated before the occurrence of hypotension.<sup>32</sup> Patient-related, non-modifiable demographic risk factors include older age, female sex, Hispanic ethnicity and longer dialysis vintage.<sup>5,12</sup> Patient co-morbidities associated with risk for IDH include diabetes mellitus, coronary artery disease, systolic dysfunction, left ventricular hypertrophy and elevated cardiac troponin<sup>5,12,20,21,33,34</sup>. Patient

factors that are more amenable to treatment and change include hyperphosphatemia, anti-hypertensive medication use, ingestion of a meal before hemodialysis, increased body mass index, lower albumin levels, and interdialytic weight gain.<sup>5,12,35–37</sup>

Related to the dialysis prescription, UFR and total volume removal is an associated risk factor IDH<sup>5,12</sup> and UFR is independently associated with cardiovascular mortality.<sup>38–40</sup> Other dialysis-related factors include dialysate sodium and calcium levels, dialysate temperature and acetate buffers. In some, but not all studies, patients treated with low dialysate sodium ( < 135 mmol/l) have more IDH<sup>41–43</sup> while higher dialysate calcium is associated with a lower incidence of this complication<sup>44</sup>. In regards to dialysate buffers, previously acetate use was frequent in the past and was demonstrated to cause frequent IDH.<sup>45,46</sup> In a non-randomized cross-over study, converting the buffer in the dialysate from acetate to bicarbonate reduced the incidence of IDH in patients by 50%<sup>47</sup> (Table 1).

## Prevention and Management of Intradialytic Hypotension (Table 2)

### Acute Management

IDH may be caused by potentially life-threatening conditions, and these must be rapidly evaluated and treated as needed. Conditions include acute hemolysis, air embolus, dialyzer reaction, coronary ischemia, pulmonary embolism, pericardial tamponade, bleeding, and sepsis<sup>48,49</sup>. Acute management steps for all causes should occur simultaneously.

Ultrafiltration should be stopped, oxygen administered, and the patient should be placed supine and in Trendelenburg position. Intravenous fluids should be administered to restore blood pressure. Isotonic 0.9% normal saline is used commonly, however the optimal resuscitation fluid is not known. One randomized controlled trial<sup>50</sup>, and a systematic review<sup>51</sup> both concluded that 5% albumin is no more effective than 0.9% saline in the treatment of IDH. Severe and/or refractory hypotension should prompt immediate patient transfer to hospital for further evaluation and management.

### Prevention

Preventive strategies should be employed in patients with recurrent episodes of IDH, and can be categorized into changes to HD treatment, patient behavior or medications.

### HD Treatment

- Patient weight – Common clinical practice entails reassessment of the “dry weight”, with progressive increase in prescribed weight with recurrent episodes of IDH. In the vast majority of outpatient HD units, scheduled treatment sessions leave individual dialysis session lengths relatively inflexible, and so the “dry weight” approach often necessitates unacceptably high ultrafiltration rates when IDWG is high. Both high IDWG<sup>52</sup> and rapid UFR greater than 10mL/hr/kg<sup>38</sup> are independently associated with mortality in HD patients. A novel approach would entail prescription of a “maximum weight”, ensuring ultrafiltration rates do not exceed 10mL/hr/kg, although this may require frequent additional treatments per week in patients with high IDWG.

- Dialysate composition – in non-hypercalcemic patients, ensure dialysate calcium is 2.25mmol/L, as lower levels have been associated with IDH<sup>53</sup>. While high dialysate sodium (>140mEq/L) or sodium modelling is commonly employed to manage IDH, these practices are associated with increased thirst and increased IDWG, and should be avoided<sup>54,55</sup>.
- Dialysate temperature – Cooling dialysate can reduce the risk of IDH. A recent meta-analysis of 26 trials reported that IDH was reduced by 68% (95% CI 44–82%) when using cooled dialysate compared to standard temperature dialysate<sup>56</sup>. Cooling can be achieved using an empiric fixed reduction in temperature, or through a biofeedback device. The mechanism by which cooled dialysate reduced IDH is not clearly understood, but likely involves increased systemic vascular resistance by activation of the sympathetic nervous system<sup>49</sup>.
- Dialysis frequency and duration – modifying a patient’s routine hemodialysis schedule to longer hours and/or more frequent treatments per week may reduce the risk of IDH, as more frequent sessions will decrease IDWG, and longer sessions will decrease ultrafiltration rates<sup>57</sup>. In refractory cases, switching dialysis modality to peritoneal dialysis may be of benefit<sup>58</sup>.
- Monitoring devices – Intradialytic monitoring of volume status and/or automated regulation of ultrafiltration rates can be achieved through several methods including hematocrit monitoring<sup>59,60</sup>, multifrequency bioimpedance<sup>61–63</sup> and biofeedback ultrafiltration<sup>64</sup>. However, use of these devices has not been established to reduce risk of IDH.

**Medications**—Holding the dose of anti-hypertensive medication immediately prior to dialysis, and preferential prescription of once daily anti-hypertensives may be of benefits for patients prone to IDH. Midodrine, a selective alpha-1 antagonist can be used off-label for the prevention of IDH and given 30 minutes prior to dialysis initiation<sup>65</sup>. However, some patients experience significant side effects of pruritus, supine hypertension, and pilomotor reactions which may limit its use.

**Patient Education**—HD patients should be educated on the benefits of a low salt diet, since limiting dietary salt intake to 5g/day lowers IDWG and decreases episodes of IDH<sup>49,66</sup>. Patients prone to IDH should also be educated on the deleterious effects of food ingestion during dialysis on blood pressure<sup>67,68</sup>.

## The Implications of Conventional “Volume Control” on Mortality

While a recent decline has been observed, mortality rates in ESRD patients still remains unacceptably high<sup>69</sup>. Understanding has grown in recent years on the impact of factors related to the clinical practice of achieving “volume control” on mortality in the ESRD population. IDH is so commonly observed in clinical practice, that clinicians may be unaware of its strong association with mortality. A prospective Japanese study of 1244 patients<sup>4</sup> demonstrated that the lowest intradialytic systolic blood pressures had the highest risk of 2 year mortality. A study from a 10,000 patient cohort reported a nadir systolic blood

pressure of  $<90\text{mmHg}$  on  $>30\%$  of treatments was associated with a 1.56 times risk of mortality compared to patients not meeting this definition of IDH<sup>3</sup>. More frequent IDH episodes is also associated with incrementally greater mortality<sup>70</sup>. Given the lack of high-quality, large interventional trials, our understanding is gained largely from observational studies. Two key factors drawn from the literature are closely interconnected clinically; interdialytic weight gain (IDWG) and UFR.

The first study to demonstrate an association between IDWG and mortality was a large US study of 34,107 hemodialysis patients over 2 years<sup>52</sup>. When interdialytic fluid gains were analyzed in 0.5 kg increments, a significant and graded rise in mortality was observed with increased fluid gain. Wong et. al analyzed associations of IDWG and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS)<sup>71</sup>. In this international study of 21,919 hemodialysis patients, IDWG of 5.7%, compared to 2.5% to  $<4\%$  was associated with significantly higher mortality. In addition, several other studies have assessed mortality after the 3-day window in every conventional thrice weekly hemodialysis schedule, when IDWG is generally highest. Karnik et al analyzed over 5 million hemodialysis treatments in over 77,000 United States hemodialysis patients and found that cardiac arrests were most likely to occur on a Monday, after the “long interdialytic interval”<sup>72</sup>. Another study of 32,065 hemodialysis patients in the United States compared death rates on the day after the long interdialytic interval compared to other days<sup>73</sup>. All-cause mortality, cardiac-related mortality and cardiac arrest were all significantly more common on the day after the long interdialytic interval than on other days. While these studies lay the foundation for our understanding of conventional “volume control” practices on mortality, they did not specifically assess the impact of UFRs during hemodialysis treatments.

Clinical practice currently widely dictates use of a prescribed “dry weight” during hemodialysis. Thus, to understand the correlations of IDWG and IDH on mortality, we must assume rapid UFRs in ESRD patients with high IDWG, in an attempt to achieve the prescribed dry weight during a relatively fixed treatment time. In an international study from DOPPS of 22,000 patients from seven countries, UFR  $> 10\text{ml/hr/kg}$  was associated with a higher risk of mortality (RR=1.09;  $p=0.02$ ), as well as a higher risk of IDH (RR = 1.33;  $p=0.045$ )<sup>74</sup>. Similarly, in a re-analysis of a HEMO study cohort of 1846 patients, Flythe et al examined the risk of mortality comparing UF rates in 3 groups:  $10\text{ml/kg/hr}$ ,  $10\text{--}13\text{ml/kg/hr}$  and greater than  $13\text{ml/kg/hr}$ <sup>38</sup>. Patients in the highest UF rate group had adjusted all-cause mortality and cardiovascular-related mortality of 1.6 and 1.7 respectively, compared to the lowest UF rate group. More recently, Assimon et al conducted a similar analysis, but with a large study cohort of 118,394 hemodialysis patients and normalized UFR to anthropometric measures such as body weight, body mass index and body surface area<sup>75</sup>. A UFR  $> 13\text{ml/hr/kg}$  was associated with a 1.3 times higher risk of mortality than UFR  $13\text{mL/hr/kg}$ . While methodologically rigorous, these studies are observational and thus residual confounding cannot be excluded. However, these results strengthen the literature and our understanding of the implications of IDH on mortality.

## The End Organ Damage from IDH: Heart, Brain and Gut

There are several postulated mechanisms by which IDH can increase risk of mortality, including myocardial stunning, ischemic brain damage, and gut endotoxin translocation. Myocardial stunning is the recurrent acute reversible segmental myocardial hypoperfusion and contractile dysfunction caused by the circulatory stress of hemodialysis. McIntyre et al have published an important series of papers which use positron emission tomography to demonstrate the deleterious effects of hemodialysis on myocardial stunning, and how this pathophysiologic process is crucially dependent on rate of ultrafiltration and IDH (including asymptomatic IHD) <sup>76-79</sup>. Recurrent myocardial stunning can result in long-term loss of myocardial contractility, which is associated with increased mortality<sup>78</sup>.

Brain imaging studies of dialysis patients have reported MRI findings of brain ischemia, including cerebral infarcts<sup>80-82</sup>, atrophy<sup>83</sup> and leukoaraosis<sup>84</sup>. Leukoaraosis is caused by ischemic injury, is a risk factor for dementia and strokes, and occurs in the vascular watershed areas of the brain<sup>79,84</sup>. Although studies are currently lacking, IDH should intuitively increase the risk of these ischemic injuries to the brain with subsequent long term consequences of cognitive decline, dementia and stroke. Studies are currently underway combining brain imaging with neurologic outcomes in the face of IDH<sup>79</sup>.

Translocation of endotoxin across the gut wall occurs in the setting of bowel edema and hypoperfusion<sup>85</sup>. Endotoxemia has been studied in CHF patients<sup>86</sup> and is a strong proinflammatory stimulus associated with the malnutrition and wasting<sup>87</sup>. Patients initiated on hemodialysis have three times the endotoxin levels of stable stage 5 CKD, likely related to poor mesenteric blood flow while on hemodialysis<sup>88,89</sup>. These high endotoxin levels contribute to the inflammation-related adverse effects on malnutrition and cardiovascular outcomes seen in dialysis patients.

## Conclusions and Recommendations

IDH is a common complication of hemodialysis therapy, with strong associations to mortality and end organ damage. Randomized controlled trials of various agents to reduce IDH such as droxidopa<sup>90</sup> and sertraline<sup>91</sup> have been conducted and show promise, but all require further testing before widespread use. Similarly, devices used during hemodialysis treatment such as hematocrit monitoring<sup>59</sup>, bioimpedance analysis<sup>63</sup> and biofeedback ultrafiltration<sup>64</sup> have been studied but also require further testing. While such exciting new drugs and devices remain on the horizon for IDH, simpler strategies can be employed in the interim. Renal fellows should be educated early in their training on the importance of proactively managing patients to avoid IDH, and steered away from centering dialysis prescriptions around a “dry weight”. Nephrologists should be cognizant that rapid UFR is strongly associated with mortality, although high quality randomized controlled trials are needed to test the hypothesis that lowering UFR reduces mortality. It may be prudent to offer additional ultrafiltration sessions for patients with large IDWGs, given that more frequent dialysis/nocturnal dialysis patients have less episodes myocardial stunning<sup>92</sup>. The current prescriptive method of volume control is often crude and requires a paradigm shift, with a proactive approach, individualized patient risk assessment and management plan.



## References

1. Workgroup KD. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. *American journal of kidney diseases : the official journal of the National Kidney Foundation*. 2005; 45(4 Suppl 3):S1–153.
2. Kooman J, Basci A, Pizzarelli F, et al. EBP guideline on haemodynamic instability. *Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association*. 2007; 22(Suppl 2):ii22–44.
3. Flythe JE, Xue H, Lynch KE, Curhan GC, Brunelli SM. Association of mortality risk with various definitions of intradialytic hypotension. *Journal of the American Society of Nephrology : JASN*. 2015; 26(3):724–734. [PubMed: 25270068]
4. Shoji T, Tsubakihara Y, Fujii M, Imai E. Hemodialysis-associated hypotension as an independent risk factor for two-year mortality in hemodialysis patients. *Kidney international*. 2004; 66(3):1212–1220. [PubMed: 15327420]
5. Tisler A, Akocsi K, Borbas B, et al. The effect of frequent or occasional dialysis-associated hypotension on survival of patients on maintenance haemodialysis. *Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association*. 2003; 18(12):2601–2605.
6. Daugirdas JT. Dialysis hypotension: a hemodynamic analysis. *Kidney international*. 1991; 39(2):233–246. [PubMed: 2002637]
7. Degoulet P, Reach I, Di Giulio S, et al. Epidemiology of dialysis induced hypotension. *Proceedings of the European Dialysis and Transplant Association European Dialysis and Transplant Association*. 1981; 18:133–138. [PubMed: 7329960]
8. Sherman RA. Intradialytic hypotension: an overview of recent, unresolved and overlooked issues. *Seminars in dialysis*. 2002; 15(3):141–143. [PubMed: 12100450]
9. Davenport A, Cox C, Thuraisingham R. Blood pressure control and symptomatic intradialytic hypotension in diabetic haemodialysis patients: a cross-sectional survey. *Nephron Clinical practice*. 2008; 109(2):c65–71. [PubMed: 18560240]
10. Davenport A, Cox C, Thuraisingham R. Achieving blood pressure targets during dialysis improves control but increases intradialytic hypotension. *Kidney international*. 2008; 73(6):759–764. [PubMed: 18160959]
11. Palmer BF, Henrich WL. Recent advances in the prevention and management of intradialytic hypotension. *Journal of the American Society of Nephrology : JASN*. 2008; 19(1):8–11. [PubMed: 18178796]
12. Sands JJ, Usvyat LA, Sullivan T, et al. Intradialytic hypotension: frequency, sources of variation and correlation with clinical outcome. *Hemodialysis international International Symposium on Home Hemodialysis*. 2014; 18(2):415–422. [PubMed: 24467830]
13. Silversides JA, Pinto R, Kuint R, et al. Fluid balance, intradialytic hypotension, and outcomes in critically ill patients undergoing renal replacement therapy: a cohort study. *Critical care*. 2014; 18(6):624. [PubMed: 25407408]
14. Rothe CF. Reflex control of veins and vascular capacitance. *Physiological reviews*. 1983; 63(4):1281–1342. [PubMed: 6361810]
15. Sander-Jensen K, Mehlsen J, Stadeager C, et al. Increase in vagal activity during hypotensive lower-body negative pressure in humans. *The American journal of physiology*. 1988; 255(1 Pt 2):R149–156. [PubMed: 3394838]
16. Ushioda E, Nuwayhid B, Kleinman G, Tabsh K, Brinkman CR 3rd, Assali NS. The contribution of the beta-adrenergic system to the cardiovascular response to hypovolemia. *American journal of obstetrics and gynecology*. 1983; 147(4):423–429. [PubMed: 6312800]
17. Shen YT, Knight DR, Thomas JX Jr, Vatner SF. Relative roles of cardiac receptors and arterial baroreceptors during hemorrhage in conscious dogs. *Circulation research*. 1990; 66(2):397–405. [PubMed: 2297811]
18. Hintze TH, Vatner SF. Cardiac dynamics during hemorrhage. Relative unimportance of adrenergic inotropic responses. *Circulation research*. 1982; 50(5):705–713. [PubMed: 7074732]

19. Ie EH, Krams R, Vletter WB, Nette RW, Weimar W, Zietse R. Myocardial contractility does not determine the haemodynamic response during dialysis. *Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association*. 2005; 20(11):2465–2471.
20. van der Sande FM, Mulder AW, Hoortje SJ, et al. The hemodynamic effect of different ultrafiltration rates in patients with cardiac failure and patients without cardiac failure: comparison between isolated ultrafiltration and ultrafiltration with dialysis. *Clinical nephrology*. 1998; 50(5): 301–308. [PubMed: 9840318]
21. Ritz E, Rambaesk M, Mall G, Ruffmann K, Mandelbaum A. Cardiac changes in uraemia and their possible relationship to cardiovascular instability on dialysis. *Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association*. 1990; 5(Suppl 1):93–97.
22. Leunissen KM, Cheriex EC, Janssen J, et al. Influence of left ventricular function on changes in plasma volume during acetate and bicarbonate dialysis. *Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association*. 1987; 2(2):99–103.
23. Chesterton LJ, Selby NM, Burton JO, Fialova J, Chan C, McIntyre CW. Categorization of the hemodynamic response to hemodialysis: the importance of baroreflex sensitivity. *Hemodialysis international International Symposium on Home Hemodialysis*. 2010; 14(1):18–28. [PubMed: 19888950]
24. Tinucci T, Abrahao SB, Santello JL, Mion D Jr. Mild chronic renal insufficiency induces sympathetic overactivity. *Journal of human hypertension*. 2001; 15(6):401–406. [PubMed: 11439315]
25. Seals DR, Dinenna FA. Collateral damage: cardiovascular consequences of chronic sympathetic activation with human aging. *American journal of physiology Heart and circulatory physiology*. 2004; 287(5):H1895–1905. [PubMed: 15475526]
26. Rubinger D, Revis N, Pollak A, Luria MH, Sapoznikov D. Predictors of haemodynamic instability and heart rate variability during haemodialysis. *Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association*. 2004; 19(8):2053–2060.
27. Converse RL Jr, Jacobsen TN, Toto RD, et al. Sympathetic overactivity in patients with chronic renal failure. *The New England journal of medicine*. 1992; 327(27):1912–1918. [PubMed: 1454086]
28. Tong YQ, Hou HM. Alteration of heart rate variability parameters in nondiabetic hemodialysis patients. *American journal of nephrology*. 2007; 27(1):63–69. [PubMed: 17259695]
29. Monahan KD. Effect of aging on baroreflex function in humans. *American journal of physiology Regulatory, integrative and comparative physiology*. 2007; 293(1):R3–R12.
30. Baskett PJ. ABC of major trauma. Management of hypovolaemic shock. *Bmj*. 1990; 300(6737): 1453–1457. [PubMed: 2198971]
31. Meinke L, Lighthall GK. Fluid management in hospitalized patients. *Comprehensive therapy*. 2005; 31(3):209–223. [PubMed: 16110129]
32. Barth C, Boer W, Garzoni D, et al. Characteristics of hypotension-prone haemodialysis patients: is there a critical relative blood volume? *Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association*. 2003; 18(7): 1353–1360.
33. Chao CT, Huang JW, Yen CJ. Intradialytic hypotension and cardiac remodeling: a vicious cycle. *BioMed research international*. 2015; 2015:724147. [PubMed: 25654122]
34. Hung SY, Hung YM, Fang HC, et al. Cardiac troponin I and creatine kinase isoenzyme MB in patients with intradialytic hypotension. *Blood Purif*. 2004; 22(4):338–343. [PubMed: 15218282]
35. Nakamoto H, Honda N, Mimura T, Suzuki H. Hypoalbuminemia is an important risk factor of hypotension during hemodialysis. *Hemodialysis international International Symposium on Home Hemodialysis*. 2006; 10(Suppl 2):S10–15. [PubMed: 17022744]

36. Stefansson BV, Brunelli SM, Cabrera C, et al. Intradialytic hypotension and risk of cardiovascular disease. *Clinical journal of the American Society of Nephrology : CJASN*. 2014; 9(12):2124–2132. [PubMed: 25376764]
37. Takeda A, Toda T, Fujii T, Sasaki S, Matsui N. Can predialysis hypertension prevent intradialytic hypotension in hemodialysis patients? *Nephron Clin Pract*. 2006; 103(4):c137–143. [PubMed: 16636581]
38. Flythe JE, Kimmel SE, Brunelli SM. Rapid fluid removal during dialysis is associated with cardiovascular morbidity and mortality. *Kidney international*. 2011; 79(2):250–257. [PubMed: 20927040]
39. Movilli E, Gaggia P, Zubani R, et al. Association between high ultrafiltration rates and mortality in uraemic patients on regular haemodialysis. A 5-year prospective observational multicentre study. *Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association*. 2007; 22(12):3547–3552.
40. Saran R, Bragg-Gresham JL, Levin NW, et al. Longer treatment time and slower ultrafiltration in hemodialysis: associations with reduced mortality in the DOPPS. *Kidney international*. 2006; 69(7):1222–1228. [PubMed: 16609686]
41. Levine J, Falk B, Henriquez M, Raja RM, Kramer MS, Rosenbaum JL. Effects of varying dialysate sodium using large surface area dialyzers. *Transactions - American Society for Artificial Internal Organs*. 1978; 24:139–141. [PubMed: 715990]
42. Raja R, Kramer M, Barber K, Chen S. Sequential changes in dialysate sodium (DNa) during hemodialysis. *Transactions - American Society for Artificial Internal Organs*. 1983; 29:649–651. [PubMed: 6673305]
43. Stewart WK, Fleming LW, Manuel MA. Benefits obtained by the use of high sodium dialysate during maintenance haemodialysis. *Proceedings of the European Dialysis and Transplant Association European Dialysis and Transplant Association*. 1972; 9:111–118. [PubMed: 4668903]
44. Kyriazis J, Stamatidis D, Mamouna A. Intradialytic and interdialytic effects of treatment with 1.25 and 1.75 Mmol/L of calcium dialysate on arterial compliance in patients on hemodialysis. *American journal of kidney diseases : the official journal of the National Kidney Foundation*. 2000; 35(6):1096–1103. [PubMed: 10845823]
45. Malberti F, Surian M, Colussi G, Minetti L. The influence of dialysis fluid composition on dialysis tolerance. *Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association*. 1987; 2(2):93–98.
46. Noris M, Todeschini M, Casiraghi F, et al. Effect of acetate, bicarbonate dialysis, and acetate-free biofiltration on nitric oxide synthesis: implications for dialysis hypotension. *American journal of kidney diseases : the official journal of the National Kidney Foundation*. 1998; 32(1):115–124. [PubMed: 9669432]
47. Man NK, Fournier G, Thireau P, Gaillard JL, Funck-Brentano JL. Effect of bicarbonate-containing dialysate on chronic hemodialysis patients: a comparative study. *Artificial organs*. 1982; 6(4):421–428. [PubMed: 7165557]
48. Assimon MM, Flythe JE. Intradialytic Blood Pressure Abnormalities: The Highs, The Lows and All That Lies Between. *Am J Nephrol*. 2015; 42(5):337–350. [PubMed: 26584275]
49. Gul A, Miskulin D, Harford A, Zager P. Intradialytic hypotension. *Curr Opin Nephrol Hypertens*. 2016; 25(6):545–550. [PubMed: 27606498]
50. Knoll GA, Grabowski JA, Dervin GF, O'Rourke K. A randomized, controlled trial of albumin versus saline for the treatment of intradialytic hypotension. *J Am Soc Nephrol*. 2004; 15(2):487–492. [PubMed: 14747397]
51. Fortin PM, Bassett K, Musini VM. Human albumin for intradialytic hypotension in haemodialysis patients. *Cochrane Database Syst Rev*. 2010; (11):CD006758. [PubMed: 21069691]
52. Kalantar-Zadeh K, Regidor DL, Kovesdy CP, et al. Fluid retention is associated with cardiovascular mortality in patients undergoing long-term hemodialysis. *Circulation*. 2009; 119(5):671–679. [PubMed: 19171851]
53. van der Sande FM, Cheriex EC, van Kuijk WH, Leunissen KM. Effect of dialysate calcium concentrations on intradialytic blood pressure course in cardiac-compromised patients. *Am J Kidney Dis*. 1998; 32(1):125–131. [PubMed: 9669433]

54. Penne EL, Sergeyeva O. Sodium gradient: a tool to individualize dialysate sodium prescription in chronic hemodialysis patients? *Blood Purif.* 2011; 31(1–3):86–91. [PubMed: 21228573]
55. Keen ML, Gotch FA. The association of the sodium “setpoint” to interdialytic weight gain and blood pressure in hemodialysis patients. *Int J Artif Organs.* 2007; 30(11):971–979. [PubMed: 18067098]
56. Mustafa RA, Bdair F, Akl EA, et al. Effect of Lowering the Dialysate Temperature in Chronic Hemodialysis: A Systematic Review and Meta-Analysis. *Clin J Am Soc Nephrol.* 2016; 11(3): 442–457. [PubMed: 26712807]
57. Kotanko P, Garg AX, Depner T, et al. Effects of frequent hemodialysis on blood pressure: Results from the randomized frequent hemodialysis network trials. *Hemodial Int.* 2015; 19(3):386–401. [PubMed: 25560227]
58. Merino JL, Rivera M, Teruel JL, Marcén R, Ortuño J. CAPD as treatment of chronic debilitating hemodialysis hypotension. *Perit Dial Int.* 2002; 22(3):429. [PubMed: 12227409]
59. Reddan DN, Szczech LA, Hasselblad V, et al. Intradialytic blood volume monitoring in ambulatory hemodialysis patients: A randomized trial. *Journal of the American Society of Nephrology.* 2005; 16(7):2162–2169. [PubMed: 15930095]
60. Agarwal R, Kelley K, Light RP. Diagnostic utility of blood volume monitoring in hemodialysis patients. *Am J Kidney Dis.* 2008; 51(2):242–254. [PubMed: 18215702]
61. Hur E, Usta M, Toz H, et al. Effect of fluid management guided by bioimpedance spectroscopy on cardiovascular parameters in hemodialysis patients: a randomized controlled trial. *Am J Kidney Dis.* 2013; 61(6):957–965. [PubMed: 23415416]
62. Onofriescu M, Hogas S, Voroneanu L, et al. Bioimpedance-guided fluid management in maintenance hemodialysis: a pilot randomized controlled trial. *Am J Kidney Dis.* 2014; 64(1): 111–118. [PubMed: 24583055]
63. Wizemann V, Wabel P, Chamney P, et al. The mortality risk of overhydration in haemodialysis patients. *Nephrol Dial Transplant.* 2009; 24(5):1574–1579. [PubMed: 19131355]
64. Leung KCW, Quinn RR, Ravani P, MacRae JM. Ultrafiltration biofeedback guided by blood volume monitoring to reduce intradialytic hypotensive episodes in hemodialysis: study protocol for a randomized controlled trial. *Trials.* 2014;15. [PubMed: 24405854]
65. Prakash S, Garg AX, Heidenheim AP, House AA. Midodrine appears to be safe and effective for dialysis-induced hypotension: a systematic review. *Nephrol Dial Transplant.* 2004; 19(10):2553–2558. [PubMed: 15280522]
66. Kayikcioglu M, Tumuklu M, Ozkahya M, et al. The benefit of salt restriction in the treatment of end-stage renal disease by haemodialysis. *Nephrol Dial Transplant.* 2009; 24(3):956–962. [PubMed: 19004849]
67. Sherman RA, Torres F, Cody RP. Postprandial blood pressure changes during hemodialysis. *Am J Kidney Dis.* 1988; 12(1):37–39. [PubMed: 3389352]
68. Barakat MM, Nawab ZM, Yu AW, Lau AH, Ing TS, Daugirdas JT. Hemodynamic effects of intradialytic food ingestion and the effects of caffeine. *J Am Soc Nephrol.* 1993; 3(11):1813–1818. [PubMed: 8329676]
69. Saran R, Robinson B, Shahinian V. US Renal Data System 2016 Annual Data Report: epidemiology of kidney disease in the United States. *Am J Kidney Dis.* 2016 (in press).
70. Rocha A, Sousa C, Teles P, Coelho A, Xavier E. Frequency of intradialytic hypotensive episodes: old problem, new insights. *Journal of the American Society of Hypertension : JASH.* 2015; 9(10): 763–768. [PubMed: 26316015]
71. Wong MM, McCullough KP, Bieber BA, et al. Interdialytic Weight Gain: Trends, Predictors, and Associated Outcomes in the International Dialysis Outcomes and Practice Patterns Study (DOPPS). *Am J Kidney Dis.* 2016
72. Karnik JA, Young BS, Lew NL, et al. Cardiac arrest and sudden death in dialysis units. *Kidney International.* 2001; 60(1):350–357. [PubMed: 11422771]
73. Foley RN, Gilbertson DT, Murray T, Collins AJ. Long interdialytic interval and mortality among patients receiving hemodialysis. *N Engl J Med.* 2011; 365(12):1099–1107. [PubMed: 21992122]

74. Saran R, Bragg-Gresham JL, Levin NW, et al. Longer treatment time and slower ultrafiltration in hemodialysis: Associations with reduced mortality in the DOPPS. *Kidney International*. 2006; 69(7):1222–1228. [PubMed: 16609686]
75. Assimon MM, Wenger JB, Wang L, Flythe JE. Ultrafiltration Rate and Mortality in Maintenance Hemodialysis Patients. *Am J Kidney Dis*. 2016; 68(6):911–922. [PubMed: 27575009]
76. McIntyre CW, Burton JO, Selby NM, et al. Hemodialysis-induced cardiac dysfunction is associated with an acute reduction in global and segmental myocardial blood flow. *Clin J Am Soc Nephrol*. 2008; 3(1):19–26. [PubMed: 18003765]
77. Burton JO, Jefferies HJ, Selby NM, McIntyre CW. Hemodialysis-Induced Cardiac Injury: Determinants and Associated Outcomes. *Clinical Journal of the American Society of Nephrology*. 2009; 4(5):914–920. [PubMed: 19357245]
78. Burton JO, Jefferies HJ, Selby NM, McIntyre CW. Hemodialysis-induced repetitive myocardial injury results in global and segmental reduction in systolic cardiac function. *Clinical journal of the American Society of Nephrology : CJASN*. 2009; 4(12):1925–1931. [PubMed: 19808220]
79. McIntyre CW. Recurrent circulatory stress: the dark side of dialysis. *Semin Dial*. 2010; 23(5):449–451. [PubMed: 21039872]
80. Nakatani T, Naganuma T, Uchida J, et al. Silent cerebral infarction in hemodialysis patients. *Am J Nephrol*. 2003; 23(2):86–90. [PubMed: 12481146]
81. Naganuma T, Uchida J, Tsuchida K, et al. Silent cerebral infarction predicts vascular events in hemodialysis patients. *Kidney Int*. 2005; 67(6):2434–2439. [PubMed: 15882289]
82. Anan F, Shimomura T, Imagawa M, et al. Predictors for silent cerebral infarction in patients with chronic renal failure undergoing hemodialysis. *Metabolism*. 2007; 56(5):593–598. [PubMed: 17445532]
83. Prohovnik I, Post J, Uribarri J, Lee H, Sandu O, Langhoff E. Cerebrovascular effects of hemodialysis in chronic kidney disease. *J Cereb Blood Flow Metab*. 2007; 27(11):1861–1869. [PubMed: 17406658]
84. Kim CD, Lee HJ, Kim DJ, et al. High prevalence of leukoaraiosis in cerebral magnetic resonance images of patients on peritoneal dialysis. *Am J Kidney Dis*. 2007; 50(1):98–107. [PubMed: 17591529]
85. Krack A, Sharma R, Figulla HR, Anker SD. The importance of the gastrointestinal system in the pathogenesis of heart failure. *Eur Heart J*. 2005; 26(22):2368–2374. [PubMed: 15980032]
86. Charalambous BM, Stephens RC, Feavers IM, Montgomery HE. Role of bacterial endotoxin in chronic heart failure: the gut of the matter. *Shock*. 2007; 28(1):15–23. [PubMed: 17510602]
87. Yang RB, Mark MR, Gray A, et al. Toll-like receptor-2 mediates lipopolysaccharide-induced cellular signalling. *Nature*. 1998; 395(6699):284–288. [PubMed: 9751057]
88. Yu AW, Nawab ZM, Barnes WE, Lai KN, Ing TS, Daugirdas JT. Splanchnic erythrocyte content decreases during hemodialysis: a new compensatory mechanism for hypovolemia. *Kidney Int*. 1997; 51(6):1986–1990. [PubMed: 9186892]
89. Jakob SM, Ruokonen E, Vuolteenaho O, Lampainen E, Takala J. Splanchnic perfusion during hemodialysis: evidence for marginal tissue perfusion. *Crit Care Med*. 2001; 29(7):1393–1398. [PubMed: 11445693]
90. Vannorsdall MD, Hariachar S, Hewitt LA. A randomized, placebo-controlled, phase 2 study of the efficacy and safety of droxidopa in patients with intradialytic hypotension. *Postgrad Med*. 2015; 127(2):133–143. [PubMed: 25708022]
91. Razeghi E, Dashti-Khavidaki S, Nassiri S, et al. A randomized crossover clinical trial of sertraline for intradialytic hypotension. *Iran J Kidney Dis*. 2015; 9(4):323–330. [PubMed: 26174461]
92. Jefferies HJ, Virk B, Schiller B, Moran J, McIntyre CW. Frequent hemodialysis schedules are associated with reduced levels of dialysis-induced cardiac injury (myocardial stunning). *Clinical Journal of the American Society of Nephrology*. 2011; 6(6):1326–1332. [PubMed: 21597028]

**Table 1**

## Risk factors for Intradialytic Hypotension

Risk Factor	Reference	Effect on Intradialytic Hypotension	Comments
<b>Patient-related Factors</b>			
<b>Demographics</b>			
Increasing age	Tisler 2003	+	
	Sands 2014	+	
Male sex	Tisler 2003	-	
	Sands 2014	-	
Hispanic ethnicity	Sands 2014	+	
Longer hemodialysis vintage	Sands 2014	+	
<b>Co-Morbid Disease</b>			
Diabetes mellitus	Sands 2014	+	Systolic Dysfunction LVH Elevated cardiac Tn
	Takeda 2006	+	
Coronary artery disease	Tisler 2003	+	
Cardiac Dysfunction	Van der Sande 1998	+	
	Chao 2015	+	
	Hung 2014	+	
<b>Other Patient Factors</b>			
Hyperphosphatemia	Tisler 2003	+	CCB, nitrate use
Anti-hypertensive medications	Tisler 2003	+	
	Takeda 2006	-	
Higher BMI	Sands 2014	+	
Lower albumin	Nakamoto 2006	+	
Diuretic Use	Tisler 2003	-	
<b>Hemodialysis-related Factors</b>			
Increased IDWG	Stefansson 2014	+	
	Takeda 2006	+	
Lower pre-dialysis BP	Sands 2014	+	
	Takeda 2006	-	
Increased UFR	Sands 2014	+	>10mL/hr/kg increases risk
	Van der Sande 1998	+	
	Flythe 2011	+	>13mL/hr/kg highest risk
	Movilli 2007	+	
	Saran 2006	+	
Lower dialysate sodium	Levine 1978	-	Dialysate Na 135 mmol/L

Risk Factor	Reference	Effect on Intradialytic Hypotension	Comments
	Raja 1983 Steward 1972	- -	
Lower dialysate calcium	Kyriazis 2000	+	
Acetate buffer	Noris 1998	+	
Longer interdialytic interval	Sands 2014	+	

LVH: Left ventricular hypertrophy; Tn: troponin; BMI: body mass index; IDWG: interdialytic weight gain; BP: blood pressure; UFR: ultrafiltration rate; CCB: calcium channel blocker

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

**Table 2**

## Prevention and Management of Intradialytic Hypotension

ACUTE MANAGEMENT <sup>a</sup>	
Evaluation for life-threatening causes	Hemolysis, Air embolus, Dialyzer reaction, Coronary ischemia, Pulmonary embolus Pericardial tamponade, Bleeding Sepsis
Stop Ultrafiltration	
Place patient in Trendelenburg	
Administer Oxygen	
Replace intravascular volume	
Early termination of dialysis and transfer to hospital, if IDH is severe and/or refractory	
PREVENTION	
I. Patient Education	
Low salt diet	5g/day to reduce IDWG
Avoid eating during dialysis	To prevent drop in peripheral vascular resistance
II. HD treatment	
Weight	Avoid "dry weight" goal if it necessitates UFR >10mL/hr/kg
Dialysate Calcium	Keep 2.25 mmol/L
Dialysate Temperature	Empiric reduction by 0.5 or 1.0°F, or isothermic biofeedback reduction
Dialysis Frequency or modality	More frequent and/or longer hemodialysis. If IDH refractory, consider peritoneal dialysis
Monitoring devices	Blood volume monitoring, bioimpedance, biofeedback ultrafiltration
Dialysate Sodium	Sodium modelling and/or high sodium (>140mEq/L) not recommended, as associated with increased IDWG
III. Medication	
Stop anti-hypertensives prior to hemodialysis	Preferential use of once or twice daily medication dosing
Midodrine	Use limited by side effects (pruritus, pilomotor reactions)

<sup>a</sup>Steps in acute management should occur simultaneously

IDH: intradialytic hypotension; IDWG: Interdialytic weight gain; HD: hemodialysis;